JP2019081719A - Skin external preparation or internal preparation - Google Patents
Skin external preparation or internal preparation Download PDFInfo
- Publication number
- JP2019081719A JP2019081719A JP2017209186A JP2017209186A JP2019081719A JP 2019081719 A JP2019081719 A JP 2019081719A JP 2017209186 A JP2017209186 A JP 2017209186A JP 2017209186 A JP2017209186 A JP 2017209186A JP 2019081719 A JP2019081719 A JP 2019081719A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- olivine
- present
- color number
- gardner color
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 60
- 239000010450 olivine Substances 0.000 claims description 42
- 229910052609 olivine Inorganic materials 0.000 claims description 42
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- 230000010261 cell growth Effects 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000007952 growth promoter Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 6
- 241000218203 Coptis japonica Species 0.000 abstract description 4
- 230000009759 skin aging Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000008213 purified water Substances 0.000 description 23
- 239000000469 ethanolic extract Substances 0.000 description 21
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 15
- 239000001301 oxygen Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 229940058015 1,3-butylene glycol Drugs 0.000 description 10
- 235000019437 butane-1,3-diol Nutrition 0.000 description 10
- -1 pH adjusters Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000010998 test method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 7
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 7
- 229960002216 methylparaben Drugs 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002000 scavenging effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000007760 free radical scavenging Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229940123973 Oxygen scavenger Drugs 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 244000018795 Prunus mume Species 0.000 description 3
- 235000011158 Prunus mume Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 241000037803 Coptis deltoidea Species 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 240000009118 Corylus chinensis Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000010477 apricot oil Substances 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
Description
本発明は、活性酸素消去作用及び細胞増殖作用に優れた新規な外用剤又は内用剤に関する。 The present invention relates to a novel external or internal preparation excellent in active oxygen scavenging action and cell proliferation action.
皮膚は生体の最外層に位置し、紫外線等の影響により活性酸素が発生しやすい臓器であり、絶えずその酸素ストレスに曝されている。一方、皮膚細胞内には活性酸素消去酵素が存在しており、その能力を超える活性酸素が発生しないかぎり活性酸素の傷害から皮膚細胞を防衛している。ところが、皮膚細胞内の活性酸素消去酵素の活性は加齢とともに低下することが知られており、活性酸素による傷害がその防御反応を凌駕したとき、皮膚は酸化され、細胞機能が劣化して老化してゆくと考えられる。また、皮膚以外の臓器においても、その活性酸素消去能を超える活性酸素に曝されたとき、機能低下が起こり、老化したり、ガンや心筋梗塞など様々な生活習慣病が発症したりすると考えられる。そこで、活性酸素による傷害からの防衛を目的として活性酸素消去剤や抗酸化剤が検討され、ＳＯＤやカタラーゼ等の活性酸素消去酵素、ＳＯＤ様活性物質などの活性酸素消去剤や抗酸化剤を配合した食品、化粧品、医薬部外品及び医薬品等が開発されている（特許文献１，２参照）。 The skin is located in the outermost layer of a living body, is an organ which is apt to generate active oxygen under the influence of ultraviolet light and the like, and is constantly exposed to the oxygen stress. On the other hand, there is an active oxygen scavenging enzyme in skin cells, and it protects skin cells from active oxygen damage unless active oxygen exceeding its capacity is generated. However, it is known that the activity of active oxygen scavenging enzymes in skin cells decreases with age, and when injury by active oxygen surpasses its protective response, the skin is oxidized, cell function is deteriorated and aging is caused. It is thought that it will continue. In addition, in organs other than the skin, when exposed to active oxygen exceeding its active oxygen scavenging ability, it is thought that functional decline occurs, aging, and various lifestyle-related diseases such as cancer and myocardial infarction develop . Therefore, reactive oxygen scavengers and antioxidants are studied for the purpose of defense against injury by reactive oxygen, and reactive oxygen scavengers such as SOD and catalase, and active oxygen scavengers and antioxidants such as SOD-like active substances are incorporated. Food, cosmetics, quasi-drugs, medicines, etc. have been developed (see Patent Documents 1 and 2).
加齢とともに表皮角化細胞の増殖・分裂能は低下し、表皮層自体は薄くなる（非特許文献１）。生体因子であるＥｐｉｄｅｒｍａｌ Ｇｒｏｗｔｈ Ｆａｃｔｏｒ（ＥＧＦ／上皮細胞成長因子）や女性ホルモン（エストロゲン）は、表皮角化細胞の増殖に働きかけるが、加齢と共にその分泌は低下する。このような加齢による角化細胞代謝機能の低下は、表皮のターンオーバー速度を遅らせ、皮膚の老化の原因となる。また、角層表面から剥がれ落ちる角層細胞が滞留することで、表皮内メラニンの排泄がスムーズに行われなくなり、色素沈着や肌のくすみの原因となる。さらに表皮の創傷治癒が遅くなることなども知られている。これらの現象の進行を防止あるいは改善するために、角化細胞の増殖を促進させる成分の探索や、多くの皮膚外用剤の提案がなされてきた。 The ability of epidermal keratinocytes to proliferate and divide decreases with age, and the epidermal layer itself becomes thinner (Non-patent Document 1). Biological factors, such as Epidermal Growth Factor (EGF / epidermal growth factor) and female hormone (estrogen), act on the proliferation of epidermal keratinocytes, but their secretion decreases with age. Such age-related decline in keratinocyte metabolic function slows the turnover rate of the epidermis and causes skin aging. In addition, since stratum corneum cells falling off from the stratum corneum surface stay, the excretion of melanin in the epidermis can not be smoothly performed, which causes pigmentation and skin dullness. Furthermore, it is also known that wound healing of the epidermis is delayed. In order to prevent or ameliorate the progress of these phenomena, a search has been made for a component that promotes the proliferation of keratinocytes, and many proposals for external skin preparations have been made.
本発明は、抗酸化効果に優れ、且つ角化細胞増殖効果に優れた新規な皮膚外用剤又は内用剤を提供することを課題とする。 An object of the present invention is to provide a novel external skin preparation or internal skin preparation which is excellent in antioxidative effect and excellent in keratinocyte proliferation effect.
本発明者らは、この問題点を解決すべく、鋭意検討を重ねた結果、本発明のオウレンの抽出物に優れた抗酸化効果、および角化細胞増殖効果を発見し、本発明を完成するに至った。 As a result of intensive studies to solve this problem, the present inventors discover excellent antioxidant effects and keratinocyte proliferation effects on the extract of the olivine of the present invention, and complete the present invention It came to
すなわち、本発明は、以下の（１）〜（３）からなる。 That is, the present invention consists of the following (1) to (3).
（１）オウレンの抽出物を含有する皮膚外用剤であって、これに用いるオウレンとして、オウレンを常圧にて９８〜１００℃の水によって１時間抽出し、固形分濃度が０．３重量％水溶液となるように調製したとき、その溶液のガードナー色数が７−から９−の色相を示すオウレンを用いることを特徴とする皮膚外用剤。
（２）オウレンの抽出物を含有する抗酸化剤であって、これに用いるオウレンとして、オウレンを常圧にて９８〜１００℃の水によって１時間抽出し、固形分濃度が０．３重量％水溶液となるように調製したとき、その溶液のガードナー色数が７−から９−の色相を示すオウレンを用いることを特徴とする抗酸化剤。
（３）オウレンの抽出物を含有する細胞増殖促進剤であって、これに用いるオウレンとして、オウレンを常圧にて９８〜１００℃の水によって１時間抽出し、固形分濃度が０．３重量％水溶液となるように調製したとき、その溶液のガードナー色数が７−から９−の色相を示すオウレンを用いることを特徴とする細胞増殖促進剤。
(1) An external preparation for skin containing an extract of an orange extract, which is an orange extract to be used for extracting an orange extract with water at 98 to 100 ° C. under normal pressure for 1 hour, and having a solid content concentration of 0.3% by weight An external preparation for skin characterized in that, when it is prepared so as to be an aqueous solution, an orange pigment having a Gardner color number of 7- to 9- is used.
(2) An anti-oxidant containing an extract of an olivine, which is an olivine used for this, and is extracted with water at 98 to 100 ° C. for 1 hour under atmospheric pressure, and the solid content concentration is 0.3% by weight What is claimed is: 1. An antioxidant comprising, when it is prepared to be an aqueous solution, an ouren having a Gardner color number of 7- to 9- in the solution.
(3) A cell growth promoting agent containing an extract of an olivine, which is an olivine used for this, wherein the orange is extracted with water at 98 to 100 ° C. under normal pressure for 1 hour, and the solid concentration is 0.3 weight What is claimed is: 1. A cell proliferation promoter characterized by using an orange which shows that the Gardner color number of the solution is 7- to 9- when it is prepared to be a% aqueous solution.
本発明のオウレンの抽出物は、優れた抗酸化効果、細胞増殖効果を有しており、医薬品、医薬部外品、化粧品、食品の分野において貢献できるものである。 The extract of the olivine of the present invention has excellent antioxidative effect and cell proliferation effect, and can contribute in the fields of medicine, quasi-drugs, cosmetics and food.
以下に、本発明について詳細に述べる。 Hereinafter, the present invention will be described in detail.
本発明で用いるオウレンとは、キンポウゲ科のオウレン（学名：Ｃｏｐｔｉｓ ｊａｐｏｎｉｃａ Ｍａｋｉｎｏ）またはその他同属植物（学名：Ｃ．ｃｈｉｎｅｎｓｉｓ、Ｃ．ｄｅｌｔｏｉｄｅａ、Ｃ．ｔｅｅｔａなど）の根茎のことである。オウレンは古くから、胃出血、胃潰瘍、下痢などの様々な疾患に対する治療薬として東洋医学で広く用いられてきた。オウレンは、日本産や中国産などを用いることができ、基原植物としては、キクバオウレン、セリバオウレン、コセリバオウレンなどが挙げられる。また、本発明で用いるオウレンは、根茎を、常圧にて９８〜１００℃の水によって１時間抽出した抽出固形物の０．３重量％水溶液に対して、ガードナー色数試験法における色数試験を行ったとき、ガードナー色数が７−から９−、好ましくは７から８＋、より好ましくは７＋から８の色相であるオウレンを用いることができる。 The term "ouren" used in the present invention refers to the rhizome of the terminalis (Coptis japonica Makino) of the buttercup family or other congeners (scientific name: C. chinensis, C. deltoidea, C. teeta, etc.). Uranus has long been widely used in oriental medicine as a treatment for various diseases such as gastric bleeding, gastric ulcer, diarrhea and the like. As the olivine, Japanese origin or Chinese domestic origin can be used, and as the original plant, Kikuba ouren, seriba owure, Koseri baouren, etc. can be mentioned. In addition, for the olivine used in the present invention, the color number test in the Gardner color number test method for a 0.3% by weight aqueous solution of the extracted solid obtained by extracting the rhizome with water at 98 to 100 ° C under normal pressure for 1 hour. Can be used, which have a Gardner color number of 7- to 9-, preferably 7 to 8+, and more preferably 7+ to 8, respectively.
ガードナー色数とは、日本工業規格に規定されている規格の一つであり、日本工業規格 ＪＩＳ Ｋ ００７１−２ 化学製品の色試験方法−第２部：ガードナー色数に基づき、測定できる。具体的には、ヘキサクロロ白金（ＩＶ）酸カリウム、塩化鉄（ＩＩＩ）、塩化コバルト（ＩＩ）及び塩酸を用いて調製したガードナー色数標準液と試料の透過色を比較して、１〜１８の範囲の色数によって表される。試料をガードナー・ホルト試料管に入れ、測定用器具にセットし、試料と標準色を比較し、試料に最も近似したガードナー標準色番号をもって表示する。もし試料が二つの標準の間に位置するならば、最も近くの標準より濃いまたは薄いかで「＋」または「−」とする。 The Gardner color number is one of the standards defined in the Japanese Industrial Standard, and can be measured based on the Japanese Industrial Standard JIS K 0071-2 Color test method for chemical products-Part 2: Gardner color number. Specifically, the transmitted colors of the Gardner color standard solution prepared using potassium hexachloroplatinate (IV), iron (III) chloride, cobalt (II) chloride and hydrochloric acid are compared with those of 1 to 18 Represented by the number of colors in the range. The sample is placed in a Gardner Holt sample tube, set in a measuring instrument, the sample and standard color are compared, and displayed with the Gardner standard color number closest to the sample. If the sample is located between two standards, it will be "+" or "-" as darker or lighter than the nearest standard.
本発明に用いるガードナー色数試験法のより詳しい方法を説明する。例えば、根茎を１０ｍｍ角以下に粉砕し、精製水を加え、常圧にて９８〜１００℃で１時間抽出した後、ろ紙（例えば、アドバンテック東洋株式会社製、ろ紙Ｎｏ．５Ｃ）で濾過し、その濾液を濃縮し、固形分濃度が０．３重量％水溶液となるように調製してガードナー試験を行なうことができる。別の方法としては、前記の濾液を濃縮し、凍結乾燥した抽出固形物を０．３重量％になるように精製水に溶解しても良い。 A more detailed method of the Gardner color number test method used in the present invention will be described. For example, the rhizome is pulverized to a size of 10 mm square or less, purified water is added, extraction is carried out at 98 to 100 ° C. under normal pressure for 1 hour, and filtration is performed using filter paper (for example, filter paper No. 5C made by Advantec Toyo Co., Ltd.) The filtrate can be concentrated and adjusted to a solid concentration of 0.3% by weight aqueous solution to conduct the Gardner test. Alternatively, the filtrate may be concentrated and the lyophilized extract solid may be dissolved in purified water to a concentration of 0.3% by weight.
従来の一般的なオウレンは、ガードナー色数が９＋〜１２＋であり、本発明で用いるオウレンとは異なるものである。ガードナー色数が高過ぎると、効果が低くなり、澱が発生し易くなることで、皮膚外用剤に用いる際の安定性悪化に影響することがある。また、ガードナー色数が低過ぎると、有効成分が減少してしまい、効果が低くなることがある。 The conventional common ouren has a Gardner color number of 9+ to 12+, which is different from the ouren used in the present invention. If the Gardner color number is too high, the effect is low, and the occurrence of a precipitate is likely to affect the deterioration of the stability when used in a skin external preparation. In addition, when the Gardner color number is too low, the effective component may be reduced and the effect may be lowered.
本発明のオウレンの抽出物とは、本発明で用いるオウレンの根茎より抽出したものである。その抽出方法は特に限定されず、例えば、加熱抽出したものであっても良いし、常温抽出や冷蔵抽出したものであっても良い。常圧でも加圧でもよく、温度や圧力は適宜採用できる。さらに、根茎をそのまま抽出してもよいし、乾燥してから抽出してもよい。また、抽出方法はガードナー試験を行なうための抽出固形物を調製する方法と同一であっても良いし、異なっていても良い。 The extract of the olivine of the present invention is one extracted from the rhizome of the olivine used in the present invention. The extraction method is not particularly limited, and may be, for example, heat extraction, cold extraction or cold extraction. The pressure may be normal pressure or pressure, and the temperature and pressure can be appropriately adopted. Furthermore, the rhizome may be extracted as it is, or it may be extracted after being dried. In addition, the extraction method may be the same as or different from the method of preparing the extraction solid for conducting the Gardner test.
抽出する溶媒としては、例えば、水、低級アルコール類（メタノール、エタノール、１−プロパノール、２−プロパノール、１−ブタノール、２−ブタノール等）、液状多価アルコール類（１，３−ブチレングリコール、プロピレングリコール、グリセリン等）、ケトン類（アセトン、メチルエチルケトン等）、アセトニトリル、エステル類（酢酸エチル、酢酸ブチル等）、炭化水素類（ヘキサン、ヘプタン、流動パラフィン等）、エーテル類（エチルエーテル、テトラヒドロフラン、プロピルエーテル等）が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコール等の極性溶媒が良い。これらの溶媒は一種でも二種以上を混合して用いても良い。 As the solvent to be extracted, for example, water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (1, 3-butylene glycol, propylene, etc.) Glycol, glycerin etc., ketones (acetone, methyl ethyl ketone etc.), acetonitrile, esters (ethyl acetate, butyl acetate etc.), hydrocarbons (hexane, heptane, liquid paraffin etc.), ethers (ethyl ether, tetrahydrofuran, propyl) Ether etc.). Preferably, polar solvents such as water, lower alcohols and liquid polyhydric alcohols are preferable. These solvents may be used alone or in combination of two or more.
上記抽出物は、抽出した溶液のまま用いても良く、必要に応じて、濃縮、希釈及び濾過処理、活性炭等による脱色、脱臭処理等をして用いても良い。更には、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いても良い。 The extract may be used as it is as the extracted solution, and if necessary, it may be used after concentration, dilution and filtration, decolorization with activated carbon and the like, deodorization and the like. Furthermore, the extracted solution may be subjected to treatments such as concentration to dryness, spray drying, lyophilization and the like, and used as a dried product.
本発明の外用剤又は内用剤には、上記抽出物をそのまま使用しても良く、抽出物の効果を損なわない範囲内で、化粧品、医薬部外品、医薬品又は食品等に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、ｐＨ調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤、賦形剤、皮膜剤、甘味料、酸味料等の成分を含有することもできる。 In the external preparation or internal preparation of the present invention, the extract may be used as it is, as long as the effect of the extract is not impaired, it is a component used for cosmetics, quasi-drugs, medicines, foods, etc. Certain oils and fats, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, metal soaps, pH adjusters, preservatives, perfumes, moisturizers, powders, UV absorbers, thickeners, Ingredients such as dyes, antioxidants, skin lightening agents, chelating agents, excipients, coatings, sweeteners and acidulants can also be contained.
本発明の剤型としては、例えば、化粧水、クリーム、マッサージクリーム、乳液、ゲル剤、エアゾール剤、パック、洗浄剤、浴用剤、ファンデーション、打粉、口紅、軟膏、パップ剤、ペースト剤、プラスター剤、エッセンス、散剤、丸剤、錠剤、注射剤、坐剤、乳剤、カプセル剤、顆粒剤、液剤（チンキ剤、流エキス剤、酒精剤、懸濁剤、リモナーデ剤等を含む）等が挙げられる。 As a dosage form of the present invention, for example, lotions, creams, massage creams, emulsions, gels, aerosols, packs, cleaners, bath preparations, foundations, dusting, lipsticks, ointments, patches, pastes, plasters Essences, powders, pills, tablets, injections, suppositories, emulsions, capsules, granules, solutions (including tinctures, flow extracts, spirits, suspensions, limonades, etc.) .
本発明に用いる上記抽出物の含有量は、外用の場合、全量に対し、固形物に換算して０．０００１重量％以上が好ましく、０．００１〜１０重量％がより好ましい。さらに、０．０１〜５重量％が最も好ましい。０．０００１重量％未満では十分な効果は望みにくい。１０重量％を越えて含有した場合、効果の増強は認められにくく不経済である。一方、内用の場合、投与量は年齢、体重、症状、治療効果、投与方法、処理時間等により異なるが、通常、成人１人当たりの１日の量としては、５ｍｇ以上が好ましく、１０ｍｇ〜５ｇがより好ましい。さらに、１００ｍｇ〜１ｇが最も好ましい。 In the case of external use, the content of the extract used in the present invention is preferably 0.0001% by weight or more, more preferably 0.001 to 10% by weight, in terms of solid matter, with respect to the total amount. Furthermore, 0.01 to 5% by weight is most preferable. If it is less than 0.0001% by weight, it is difficult to obtain a sufficient effect. When the content is more than 10% by weight, the effect is difficult to be recognized and it is uneconomical. On the other hand, in the case of internal use, the dosage varies depending on the age, body weight, symptoms, treatment effect, administration method, treatment time etc. Usually, 5 mg or more is preferable as a daily dose per adult, and 10 mg to 5 g Is more preferred. Furthermore, 100 mg to 1 g is most preferable.
次に本発明を詳細に説明するため、実施例として本発明に用いる抽出物の製造例、処方例及び実験例を挙げるが、本発明はこれに限定されるものではない。実施例に示す含有量の部とは重量部を、％とは重量％を示す。また、以下に用いるオウレンは乾燥物を用いた。 Next, in order to explain the present invention in detail, preparation examples, formulation examples and experimental examples of the extract used in the present invention are given as examples, but the present invention is not limited thereto. In the examples, "parts of content" means "parts by weight" and "%" means% by weight. Moreover, the omelet used below used the dried material.
入手先の異なるオウレン（入手先Ａ〜Ｅ）について、それぞれのガードナー色数を測定した。 The Gardner color number was measured for each of the different sources (A to E).
本発明のオウレン（入手先Ａ）のガードナー色数
入手先Ａのオウレンの根茎３ｇを１０ｍｍ角以下に粉砕し、精製水６０ｍＬを加え、常圧にて９８〜１００℃で１時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して熱水抽出物を得た。この熱水抽出物を、精製水に再溶解した０．３重量％水溶液に対して、ガードナー色数試験法における色数試験を行ったときのガードナー色数は、８−の色相であった。
Gardner color number of the olivine of the present invention (destination A) 3 g of rhizomes of the olivine from source A are ground to 10 mm square or less, 60 mL of purified water is added, and extraction is carried out at 98 to 100 ° C. for 1 hour under normal pressure Filter and concentrate the filtrate and lyophilize to obtain a hot water extract. The Gardner color number when the color number test in the Gardner color number test method was performed on a 0.3% by weight aqueous solution obtained by re-dissolving this hot water extract in purified water had a hue of 8-.
従来のオウレン（入手先Ｂ）のガードナー色数
入手先Ｂのオウレンの根茎３ｇを１０ｍｍ角以下に粉砕し、精製水６０ｍＬを加え、常圧にて９８〜１００℃で１時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して熱水抽出物を得た。この熱水抽出物を、精製水に再溶解した０．３重量％水溶液に対して、ガードナー色数試験法における色数試験を行ったときのガードナー色数は、１１＋の色相であった。
A conventional Gardner color number of our olivine (source B) 3 g of rhizome of olivine B is ground to 10 mm square or less, 60 mL of purified water is added, and extraction is carried out at 98 to 100 ° C. under normal pressure for 1 hour, followed by filtration. The filtrate was concentrated and lyophilized to give a hot water extract. The Gardner color number when the color number test in the Gardner color number test method was performed on a 0.3 wt% aqueous solution obtained by re-dissolving this hot water extract in purified water had a hue of 11+.
従来のオウレン（入手先Ｃ）のガードナー色数
入手先Ｃのオウレンの根茎３ｇを１０ｍｍ角以下に粉砕し、精製水６０ｍＬを加え、常圧にて９８〜１００℃で１時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して熱水抽出物を得た。この熱水抽出物を、精製水に再溶解した０．３重量％水溶液に対して、ガードナー色数試験法における色数試験を行ったときのガードナー色数は、１２−の色相であった。
A conventional Gardner color number of Uranus (source C) 3g of Rhizome rhizomes from C is crushed to 10 mm square or less, 60 mL of purified water is added, and extraction is carried out at 98 to 100 ° C. under normal pressure for 1 hour, followed by filtration. The filtrate was concentrated and lyophilized to give a hot water extract. The Gardner color number when the color number test in the Gardner color number test method was performed on a 0.3 wt% aqueous solution obtained by re-dissolving this hot water extract in purified water had a hue of 12-.
従来のオウレン（入手先Ｄ）のガードナー色数
入手先Ｄのオウレンの根茎３ｇを１０ｍｍ角以下に粉砕し、精製水６０ｍＬを加え、常圧にて９８〜１００℃で１時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して熱水抽出物を得た。この熱水抽出物を、精製水に再溶解した０．３重量％水溶液に対して、ガードナー色数試験法における色数試験を行ったときのガードナー色数は、９＋の色相であった。
A conventional Gardner color number of Uranus (Applied to D) 3 g of Rhizomes of Ord of D is crushed to 10 mm square or less, 60 mL of purified water is added, and extraction is carried out at 98 to 100 ° C. under normal pressure for 1 hour, followed by filtration. The filtrate was concentrated and lyophilized to give a hot water extract. The Gardner color number when the color number test in the Gardner color number test method was performed on a 0.3 wt% aqueous solution obtained by re-dissolving this hot water extract in purified water had a hue of 9+.
従来のオウレン（入手先Ｅ）のガードナー色数
入手先Ｅのオウレンの根茎３ｇを１０ｍｍ角以下に粉砕し、精製水６０ｍＬを加え、常圧にて９８〜１００℃で１時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して熱水抽出物を得た。この熱水抽出物を、精製水に再溶解した０．３重量％水溶液に対して、ガードナー色数試験法における色数試験を行ったときのガードナー色数は、１０−の色相であった。
A conventional Gardner color number of Uranus (Available source E) 3 g of the rhizome of Uranus obtained from E is crushed to 10 mm square or less, 60 mL of purified water is added, and extraction is carried out at 98 to 100 ° C. under normal pressure for 1 hour, followed by filtration. The filtrate was concentrated and lyophilized to give a hot water extract. The Gardner color number when the color number test in the Gardner color number test method was performed on a 0.3% by weight aqueous solution obtained by re-dissolving this hot water extract in purified water had a hue of 10-.
これらの試験結果を表１に示した。 The test results are shown in Table 1.
製造例１ 本発明のオウレンの熱水抽出物
本発明のオウレン（入手先Ａ）の根茎１０ｇに、精製水２００ｍＬを加え、９８〜１００℃で２時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して本発明のオウレンの熱水抽出物を１．５ｇ得た。
Production Example 1 Hot Water Extract of Ouran of the Present Invention 200 mL of purified water is added to 10 g of the rhizome of the present invention (the source A) of the present invention, extracted at 98-100 ° C. for 2 hours, filtered, and the filtrate is concentrated The product was lyophilized and lyophilized to obtain 1.5 g of the hot water extract of the invention.
比較製造例１ 従来のオウレンの熱水抽出物
製造例１において、本発明のオウレン（入手先Ａ）を従来のオウレン（入手先Ｂ）に置き換えて得られた熱水抽出物を従来のオウレンの熱水抽出物とした。
Comparative Production Example 1 Conventional Hot Water Extract of Japanese Apricot In the production example 1, the hot water extract obtained by replacing the present invention orange (A) with the conventional Aura (A) and then obtaining the hot water extract of the conventional Uren It was a hot water extract.
製造例２ 本発明のオウレンの５０％エタノール抽出物
本発明のオウレン（入手先Ａ）の根茎１０ｇに、５０％（Ｖ／Ｖ）エタノール水溶液２００ｍＬを加え、常温で７日間抽出した後、濾過し、その濾液を濃縮乾固して、本発明のオウレンの５０％エタノール抽出物を１．７ｇ得た。
Production Example 2 50% Ethanol Extract of the Sorachi of the Present Invention 200 mL of a 50% (V / V) aqueous solution of ethanol is added to 10 g of the rhizome of the present invention ren (the supplier A), extracted for 7 days at ordinary temperature, and filtered. The filtrate was concentrated to dryness to give 1.7 g of a 50% ethanolic extract of the olivine of the present invention.
比較製造例２ 従来のオウレンの５０％エタノール抽出物
製造例２において、本発明のオウレン（入手先Ａ）を従来のオウレン（入手先Ｂ）に置き換えて得られた５０％エタノール抽出物を従来のオウレンの５０％エタノール抽出物とした。
Comparative Production Example 2 Conventional 50% Ethanol Extract of Japanese Apricot In Production Example 2, a 50% ethanol extract obtained by replacing the A / C of the present invention (A) with the conventional A / C (A / B) It was a 50% ethanol extract of olivine.
製造例３ 本発明のオウレンの８０％エタノール抽出物
本発明のオウレン（入手先Ａ）の根茎１０ｇに、８０％（Ｖ／Ｖ）エタノール水溶液２００ｍＬを加え、常温で７日間抽出した後、濾過し、その濾液を濃縮乾固して、本発明のオウレンの８０％エタノール抽出物を１．７ｇ得た。
Production Example 3 80% ethanolic extract of the olivine of the present invention 200 mL of 80% (V / V) aqueous ethanol solution is added to 10 g of the rhizome of the olivine (source A) of the present invention and extracted for 7 days at ordinary temperature, followed by filtration. The filtrate was concentrated to dryness to give 1.7 g of an 80% ethanolic extract of ourt of the present invention.
比較製造例３ 従来のオウレンの８０％エタノール抽出物
製造例３において、本発明のオウレン（入手先Ａ）を従来のオウレン（入手先Ｂ）に置き換えて得られた８０％エタノール抽出物を従来のオウレンの８０％エタノール抽出物とした。
Comparative Production Example 3 Conventional 80% Ethanol Extract of Uranus In Production Example 3, the 80% ethanol extract obtained by replacing the aurene of the present invention (available source A) with the conventional auxin (available source B) is conventionally used. It was an 80% ethanol extract of olivine.
製造例４ 本発明のオウレンのエタノール抽出物
本発明のオウレン（入手先Ａ）の根茎１０ｇに、エタノール２００ｍＬを加え、常温で７日間抽出した後、濾過し、その濾液を濃縮乾固して、本発明のオウレンのエタノール抽出物を０．２ｇ得た。
Production Example 4 Ethanolic Extract of Ouricin of the Present Invention 200 mL of ethanol is added to 10 g of the rhizome of the present invention (the source A) of the present invention, extracted at ambient temperature for 7 days, filtered, and the filtrate is concentrated to dryness. 0.2 g of the ethanol extract of the olivine of the present invention was obtained.
比較製造例４ 従来のオウレンのエタノール抽出物
製造例４において、本発明のオウレン（入手先Ａ）を従来のオウレン（入手先Ｂ）に置き換えて得られたエタノール抽出物を従来のオウレンのエタノール抽出物とした。
Comparative Production Example 4 Conventional ethanolic extract of Japanese apricot oil In Production Example 4, ethanol extract of the present invention obtained by replacing the aurene of the present invention (available source A) with a conventional adren (available source B) It was a thing.
製造例５ 本発明のオウレンの１，３−ブチレングリコール抽出物
本発明のオウレン（入手先Ａ）の根茎２５ｇに、１，３−ブチレングリコール１００ｍＬを加え、常温で７日間抽出した後、濾過し、本発明のオウレンの１，３−ブチレングリコール抽出物を８０ｇ得た。
Production Example 5 1,3-Butylene Glycol Extract of Ouran of the Present Invention 100 mL of 1,3-Butylene Glycol is added to 25 g of the rhizome of the present invention (the source A) of the invention, and extraction is carried out for 7 days at ordinary temperature, followed by filtration. There were obtained 80 g of the 1,3-butylene glycol extract of the olivine of the present invention.
処方例１ 化粧水
処方 含有量（部）
１．本発明のオウレンの熱水抽出物（製造例１） １．０
２．１，３−ブチレングリコール ８．０
３．グリセリン ２．０
４．キサンタンガム ０．０２
５．クエン酸 ０．０１
６．クエン酸ナトリウム ０．１
７．エタノール ５．０
８．パラオキシ安息香酸メチル ０．１
９．ポリオキシエチレン硬化ヒマシ油（４０Ｅ．Ｏ．） ０．１
１０．香料 適量
１１．精製水にて全量を１００とする
［製造方法］成分１〜６及び１１と、成分７〜１０をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
Prescription example 1 Lotion prescription Content (parts)
1. Hot water extract of the olivine according to the present invention (Production Example 1) 1.0
2. 1,3-Butylene glycol 8.0
3. Glycerin 2.0
4. Xanthan gum 0.02
5. Citric acid 0.01
6. Sodium citrate 0.1
7. Ethanol 5.0
8. Methyl parahydroxybenzoate 0.1
9. Polyoxyethylene Cured Castor Oil (40E.O.) 0.1
10. Perfume amount 11. [Production method] The total amount is made 100 with purified water. Components 1 to 6 and 11 and components 7 to 10 are uniformly dissolved, and both are mixed and filtered to obtain a product.
比較処方例１ 従来の化粧水
処方例１において、本発明のオウレンの熱水抽出物（製造例１）を従来のオウレンの熱水抽出物（比較製造例１）に置き換えたものを従来の化粧水とした。
Comparative Formulation Example 1 Conventional Cosmetic Water In Formulation Example 1, the conventional hot water extract of the present invention (Production Example 1) is replaced with the conventional hot water extract (A) of the present invention. It was water.
処方例２ クリーム
処方 含有量（部）
１．本発明のオウレンの５０％エタノール抽出物（製造例２） ０．５
２．スクワラン ５．５
３．オリーブ油 ３．０
４．ステアリン酸 ２．０
５．ミツロウ ２．０
６．ミリスチン酸オクチルドデシル ３．５
７．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ３．０
８．ベヘニルアルコール １．５
９．モノステアリン酸グリセリン ２．５
１０．香料 ０．１
１１．パラオキシ安息香酸メチル ０．２
１２．１，３−ブチレングリコール ８．５
１３．精製水にて全量を１００とする
［製造方法］成分２〜９を加熱溶解して混合し、７０℃に保ち油相とする。成分１及び１１〜１３を加熱溶解して混合し、７５℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、４５℃で成分１０を加え、更に３０℃まで冷却して製品とする。
Formulation Example 2 Cream Formulation Content (parts)
1. The 50% ethanolic extract of the olivine of the present invention (Production Example 2) 0.5
2. Squalane 5.5
3. Olive oil 3.0
4. Stearic acid 2.0
5. Bee wax 2.0
6. Octyldodecyl myristate 3.5
7. Polyoxyethylene cetyl ether (20E.O.) 3.0
8. Behenyl alcohol 1.5
9. Glycerin monostearate 2.5
10. Flavoring agent 0.1
11. Methyl parahydroxybenzoate 0.2
12. 1,3-Butylene glycol 8.5
13. The total amount is made 100 with purified water. [Production method] Ingredients 2 to 9 are dissolved by heating, mixed, and kept at 70 ° C. to form an oil phase. Ingredients 1 and 11 to 13 are dissolved by heating, mixed and kept at 75 ° C. to form an aqueous phase. Add the aqueous phase to the oil phase and emulsify, cool with stirring, add ingredient 10 at 45 ° C, and further cool to 30 ° C to give a product.
処方例３ 乳液
処方 含有量（部）
１．本発明のオウレンの８０％エタノール抽出物（製造例３） ０．０１
２．スクワラン ５．０
３．オリーブ油 ５．０
４．ホホバ油 ５．０
５．セタノール １．５
６．モノステアリン酸グリセリン ２．０
７．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ３．０
８．ポリオキシエチレンソルビタンモノステアレート（２０Ｅ．Ｏ．） ２．０
９．香料 ０．１
１０．プロピレングリコール １．０
１１．グリセリン ２．０
１２．パラオキシ安息香酸メチル ０．２
１３．精製水にて全量を１００とする
［製造方法］成分１〜８を加熱溶解して混合し、７０℃に保ち油相とする。成分１０〜１３を加熱溶解して混合し、７５℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、４５℃で成分９を加え、更に３０℃まで冷却して製品とする。
Prescription example 3 Emulsion content (parts)
1. The 80% ethanolic extract of the olivine of the present invention (Production Example 3) 0.01
2. Squalane 5.0
3. Olive oil 5.0
4. Jojoba oil 5.0
5. Settanol 1.5
6. Glycerin monostearate 2.0
7. Polyoxyethylene cetyl ether (20E.O.) 3.0
8. Polyoxyethylene sorbitan monostearate (20E.O.) 2.0
9. Flavoring agent 0.1
10. Propylene glycol 1.0
11. Glycerin 2.0
12. Methyl parahydroxybenzoate 0.2
13. The total amount is made 100 with purified water. [Production method] Ingredients 1 to 8 are dissolved by heating, mixed, and kept at 70 ° C. to form an oil phase. Ingredients 10 to 13 are dissolved by heating, mixed and kept at 75 ° C. to form an aqueous phase. The water phase is added to the oil phase and emulsified, cooled with stirring, added with component 9 at 45 ° C., and further cooled to 30 ° C. to give a product.
処方例４ ゲル剤
処方 含有量（部）
１．本発明のオウレンのエタノール抽出物（製造例４） １．０
２．エタノール ５．０
３．パラオキシ安息香酸メチル ０．１
４．ポリオキシエチレン硬化ヒマシ油（６０Ｅ．Ｏ．） ０．１
５．香料 適量
６．１，３−ブチレングリコール ５．０
７．グリセリン ５．０
８．キサンタンガム ０．１
９．カルボキシビニルポリマー ０．２
１０．水酸化カリウム ０．２
１１．精製水にて全量を１００とする
［製造方法］成分１〜５と、成分６〜１１をそれぞれ均一に溶解し、両者を混合して製品とする。
Formulation example 4 Gel formulation Content (parts)
1. Ethanol extract of the olivine according to the present invention (Production Example 4) 1.0
2. Ethanol 5.0
3. Methyl parahydroxybenzoate 0.1
4. Polyoxyethylene Cured Castor Oil (60E.O.) 0.1
5. Fragrance suitable amount 6. 1, 3- butylene glycol 5.0
7. Glycerin 5.0
8. Xanthan gum 0.1
9. Carboxy vinyl polymer 0.2
10. Potassium hydroxide 0.2
11. The total amount is 100 with purified water. [Production method] Ingredients 1 to 5 and ingredients 6 to 11 are uniformly dissolved, and both are mixed to make a product.
処方例５ パック
処方 含有量（部）
１．本発明のオウレンのエタノール抽出物（製造例４） １．０
２．本発明のオウレンの１，３−ブチレングリコール抽出物（製造例５） ５．０
３．ポリビニルアルコール １２．０
４．エタノール ５．０
５．１，３−ブチレングリコール ８．０
６．パラオキシ安息香酸メチル ０．２
７．ポリオキシエチレン硬化ヒマシ油（２０Ｅ．Ｏ．） ０．５
８．クエン酸 ０．１
９．クエン酸ナトリウム ０．３
１０．香料 適量
１１．精製水にて全量を１００とする
［製造方法］成分１〜１１を均一に溶解し製品とする。
Prescription example 5 Pack prescription content (parts)
1. Ethanol extract of the olivine according to the present invention (Production Example 4) 1.0
2. 1, 3-Butylene glycol extract of the invention of the present invention (Production Example 5) 5.0
3. Polyvinyl alcohol 12.0
4. Ethanol 5.0
5.1 1,3-Butylene glycol 8.0
6. Methyl parahydroxybenzoate 0.2
7. Polyoxyethylene Cured Castor Oil (20E.O.) 0.5
8. Citric acid 0.1
9. Sodium citrate 0.3
10. Perfume amount 11. [Manufacturing method] the total amount is made 100 with purified water.
処方例６ ファンデーション
処方 含有量（部）
１．本発明のオウレンの熱水抽出物（製造例１） １．０
２．ステアリン酸 ２．４
３．ポリオキシエチレンソルビタンモノステアレート（２０Ｅ．Ｏ．） １．０
４．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ２．０
５．セタノール １．０
６．液状ラノリン ２．０
７．流動パラフィン ３．０
８．ミリスチン酸イソプロピル ６．５
９．カルボキシメチルセルロースナトリウム ０．１
１０．ベントナイト ０．５
１１．プロピレングリコール ４．０
１２．トリエタノールアミン １．１
１３．パラオキシ安息香酸メチル ０．２
１４．二酸化チタン ８．０
１５．タルク ４．０
１６．ベンガラ １．０
１７．黄酸化鉄 ２．０
１８．香料 適量
１９．精製水にて全量を１００とする
［製造方法］成分２〜８を加熱溶解し、８０℃に保ち油相とする。成分１９に成分９をよく膨潤させ、続いて、成分１及び１０〜１３を加えて均一に混合する。これに粉砕機で粉砕混合した成分１４〜１７を加え、ホモミキサーで撹拌し７５℃に保ち水相とする。この油相に水相をかき混ぜながら加え、冷却し、４５℃で成分１８を加え、かき混ぜながら３０℃まで冷却して製品とする。
Prescription example 6 Foundation Prescription Content (parts)
1. Hot water extract of the olivine according to the present invention (Production Example 1) 1.0
2. Stearic acid 2.4
3. Polyoxyethylene sorbitan monostearate (20E.O.) 1.0
4. Polyoxyethylene cetyl ether (20E.O.) 2.0
5. Settanol 1.0
6. Liquid lanolin 2.0
7. Liquid paraffin 3.0
8. Isopropyl myristate 6.5
9. Carboxymethylcellulose sodium 0.1
10. Bentonite 0.5
11. Propylene glycol 4.0
12. Triethanolamine 1.1
13. Methyl parahydroxybenzoate 0.2
14. Titanium dioxide 8.0
15. Talc 4.0
16. Bengala 1.0
17. Yellow iron oxide 2.0
18. Perfume amount 19. The total amount is made 100 with purified water. [Production method] Ingredients 2 to 8 are dissolved by heating and kept at 80 ° C. to form an oil phase. Allow component 19 to swell well, then add components 1 and 10-13 and mix uniformly. The ingredients 14-17 pulverized and mixed with a grinder are added to this, it stirs with a homomixer, and it keeps at 75 degreeC, and sets it as an aqueous phase. The water phase is added to the oil phase with stirring, cooled, component 18 is added at 45 ° C., and the product is cooled to 30 ° C. with stirring.
処方例７ 浴用剤
処方 含有量（部）
１．本発明のオウレンのエタノール抽出物（製造例４） １．０
２．炭酸水素ナトリウム ５０．０
３．黄色２０２号（１） 適量
４．香料 適量
５．硫酸ナトリウムにて全量を１００とする
［製造方法］成分１〜５を均一に混合し製品とする。
Formulation example 7 Bath agent Formulation content (parts)
1. Ethanol extract of the olivine according to the present invention (Production Example 4) 1.0
2. Sodium bicarbonate 50.0
3. Yellow No. 202 (1) Appropriate amount 4. Flavoring amount 5. The total amount is made 100 with sodium sulfate. [Production method] Ingredients 1 to 5 are uniformly mixed to make a product.
処方例８ 軟膏
処方 含有量（部）
１．本発明のオウレンの熱水抽出物（製造例１） １．０
２．本発明のオウレンの１，３−ブチレングリコール抽出物（製造例５） ５．０
３．ポリオキシエチレンセチルエーテル（３０Ｅ．Ｏ．） ２．０
４．モノステアリン酸グリセリン １０．０
５．流動パラフィン ５．０
６．セタノール ６．０
７．パラオキシ安息香酸メチル ０．１
８．プロピレングリコール １０．０
９．精製水にて全量を１００とする
［製造方法］成分３〜６を加熱溶解して混合し、７０℃に保ち油相とする。成分１、２及び７〜９を加熱溶解して混合し、７５℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら３０℃まで冷却して製品とする。
Prescription Example 8 Ointment Prescription Content (parts)
1. Hot water extract of the olivine according to the present invention (Production Example 1) 1.0
2. 1, 3-Butylene glycol extract of the invention of the present invention (Production Example 5) 5.0
3. Polyoxyethylene cetyl ether (30E.O.) 2.0
4. Glycerin monostearate 10.0
5. Liquid paraffin 5.0
6. Setanol 6.0
7. Methyl parahydroxybenzoate 0.1
8. Propylene glycol 10.0
9. The total amount is made 100 with purified water. [Production method] Ingredients 3 to 6 are dissolved by heating, mixed, and kept at 70 ° C. to form an oil phase. Ingredients 1, 2 and 7-9 are dissolved by heating, mixed, kept at 75 ° C, and made into an aqueous phase. The water phase is added to the oil phase, emulsified, and cooled to 30 ° C. while stirring to give a product.
次に、本発明の効果を詳細に説明するため、実験例を挙げる。 Next, experimental examples will be given to explain the effects of the present invention in detail.
実験例１ 活性酸素消去作用
フリーラジカル捕捉除去作用の評価を行った。陽性対照としてはアスコルビン酸を用いた。フリーラジカルのモデルとしては、安定なフリーラジカルであるα、α−ジフェニル−β−ピクリルヒドラジル（以下ＤＰＰＨとする）を用い、試料と一定の割合で一定時間反応させ、減少するラジカルの量を波長５１７ｎｍの吸光度の減少量から測定した。
Experimental Example 1 Reactive Oxygen Scavenging Action The free radical scavenging action was evaluated. Ascorbic acid was used as a positive control. As a model of free radicals, the stable free radical α, α-diphenyl-β-picrylhydrazyl (hereinafter referred to as DPPH) is used, and the amount of radicals which are reacted with the sample at a constant rate for a certain period of time Was determined from the decrease in absorbance at a wavelength of 517 nm.
フリーラジカル捕捉除去作用の測定方法
各試料を、最終濃度０．１ｍｇ／ｍＬ（アスコルビン酸は０．０２ｍｇ／ｍＬ）となるように精製水０．３ｍＬに加えた試料液に、１．０Ｍ酢酸緩衝液（ｐＨ５．５）０．１ｍＬ、無水エタノール０．４ｍＬ及び０．５ｍＭＤＰＰＨ無水エタノール溶液０．２ｍＬを加えて反応液とした。また、油溶性の試料の場合は、最終濃度０．１ｍｇ／ｍＬとなるように無水エタノール０．４ｍＬに試料を加えた試料液に、１．０Ｍ酢酸緩衝液（ｐＨ５．５）０．１ｍＬ、精製水０．３ｍＬ及び０．５ｍＭＤＰＰＨ無水エタノール溶液０．２ｍＬを加えて反応液とした。その後、３７℃で３０分間反応させ、水を対照として波長５１７ｎｍの吸光度（Ａ）を測定した。また、ブランクとして試料の代わりに精製水を用いて吸光度（Ｂ）を測定した。フリーラジカル捕捉除去率は、以下に示す式より算出した。
フリーラジカル捕捉除去率（％）＝（１−Ａ／Ｂ）×１００
Measurement method of free radical scavenging effect 1.0 M acetate buffer in the sample solution which added each sample to 0.3 mL of purified water to a final concentration of 0.1 mg / mL (ascorbic acid is 0.02 mg / mL) 0.1 mL of a solution (pH 5.5), 0.4 mL of absolute ethanol and 0.2 mL of 0.5 mM DPPH absolute ethanol solution were added to obtain a reaction solution. In the case of an oil-soluble sample, 0.1 mL of 1.0 M acetate buffer (pH 5.5) was added to a sample solution prepared by adding the sample to 0.4 mL of absolute ethanol to a final concentration of 0.1 mg / mL. 0.3 mL of purified water and 0.2 mL of 0.5 mM DPPH absolute ethanol solution were added to obtain a reaction solution. Then, the reaction was carried out at 37 ° C. for 30 minutes, and the absorbance (A) at a wavelength of 517 nm was measured using water as a control. Also, the absorbance (B) was measured using purified water instead of the sample as a blank. The free radical scavenging removal rate was calculated from the equation shown below.
Free radical scavenging removal rate (%) = (1-A / B) x 100
これらの試験結果を表２に示した。 The test results are shown in Table 2.
その結果、本発明のオウレンの抽出物（製造例１、２、４）は、従来のオウレンの抽出物（比較製造例１、２、４）と比較して優れたフリーラジカル捕捉除去作用を有していることが認められた。なお、表１に示した従来のオウレン（入手先Ｂ〜Ｅ）を用いた各抽出物についても、従来のオウレンの抽出物（比較製造例１、２、４）と同等の効果であった。 As a result, the extract of the olivine of the present invention (manufacturing examples 1, 2 and 4) has an excellent free radical scavenging and removing action as compared with the conventional olivine extract (comparative examples of manufacturing 1, 2, 4) It was recognized that In addition, it was an effect equivalent to the extract (comparative manufacture examples 1, 2 and 4) of the conventional ouren also about each extract using the conventional ouren (source B to E) shown in Table 1.
実験例２ 角化細胞増殖促進試験
角化細胞を９６ｗｅｌｌプレートに１ｗｅｌｌあたり２×１０３個播種し、各試料（最終濃度０．００１μｇ／ｍＬ）を添加した０．５％ＦＢＳを含むＤＭＥＭ培地にて、３７℃、５％ＣＯ２条件下で５日間培養した。細胞数の測定は、染色法により行った。すなわち、培養終了後培地を除き、メタノールを用いて１０分間細胞を固定した。続いて、０．１％メチレンブルーを加え、１時間細胞の染色を行った。乾燥させた後、０．１Ｎ ＨＣｌを各ｗｅｌｌに１００μＬずつ加えてよく攪拌させ、マイクロプレートリーダーを用いて６５０ｎｍの吸光度を測定した。試料未添加の細胞数をコントロールとし、コントロールに対する試料添加時の細胞数から試料の細胞増殖促進効果を評価した。
Experimental Example 2 Keratinocyte Growth Promotion Test Keratinocytes are seeded at 2 × 10 3 cells / well in a 96-well plate, and each medium (final concentration 0.001 μg / mL) was added to DMEM medium containing 0.5% FBS. Te, 37 ° C., were cultured for 5 days under 5% CO 2. The measurement of the cell number was performed by the staining method. That is, after completion of culture, the medium was removed and cells were fixed using methanol for 10 minutes. Subsequently, 0.1% methylene blue was added to stain cells for 1 hour. After drying, 100 μL of 0.1 N HCl was added to each well and stirred well, and the absorbance at 650 nm was measured using a microplate reader. The number of cells to which the sample was not added was used as a control, and the cell growth promoting effect of the sample was evaluated from the number of cells upon addition of the sample to the control.
これらの試験結果を表３に示した。 The test results are shown in Table 3.
その結果、本発明のオウレンの８０％エタノール抽出物（製造例３）に、角化細胞増殖促進効果が認められたが、従来のオウレンの８０％エタノール抽出物（比較製造例３）には角化細胞増殖促進効果が認められなかった。なお、従来のオウレン（入手先Ｂ〜Ｅ）を用いた各抽出物についても、従来のオウレンの抽出物（比較製造例３）と同様に効果は認められなかった。 As a result, the 80% ethanol extract of the invention of the present invention (Production Example 3) showed a keratinocyte growth promoting effect, but the conventional 80% ethanol extract of the product (comparative production example 3) No cell growth promoting effect was observed. In addition, the effect was not recognized similarly to the extract of the conventional ouren (comparative manufacture example 3) also about each extract using the conventional ouren (source B to E).
実験例３ 経時安定性試験
処方例１の化粧水および比較処方例１の化粧水を、４０℃条件下にて６か月間静置して経時的に観察を行ったところ、処方例１の化粧水では沈殿物の発生が認められなかったが、比較処方例１では、６か月経過時に沈殿物の発生が認められた。
Experimental Example 3 Aging Stability Test The lotion of Formulation Example 1 and the lotion of Comparative Formulation Example 1 were allowed to stand for 6 months under 40 ° C., and observed over time, the makeup of Formulation 1 being observed. In the case of water, no generation of precipitate was observed, but in Comparative Formulation Example 1, generation of precipitate was observed after 6 months.
以上のことから、本発明のオウレンの抽出物は、優れた活性酸素消去作用及び細胞増殖促進作用を有し、これを含有する内用剤又は外用剤は、活性酸素による様々な生活習慣病（癌や心筋梗塞など）や、活性酸素及び細胞増殖の遅延による皮膚の老化（色素沈着、肌のくすみ、創傷治癒の遅延）、の予防及び治療に有効である。また、本発明のオウレンの抽出物を含有した皮膚外用剤は、安定性にも優れていた。よって、本発明のオウレンの抽出物は、皮膚の老化防止といった美容分野だけでなく、医療分野にも利用でき、化粧品、医薬部外品及び医薬品等への応用が期待される。 From the above, the extract of the olivine of the present invention has excellent activity of scavenging active oxygen and cell growth promoting activity, and the internal preparation or external preparation containing it has various lifestyle-related diseases due to active oxygen ( It is effective in the prevention and treatment of cancer (myocardial infarction, myocardial infarction, etc.), and aging of skin (pigmentation, skin dullness, delayed wound healing) due to the delay of active oxygen and cell proliferation. Moreover, the skin external preparation containing the extract of the olivine of this invention was excellent also in stability. Therefore, the extract of the olivine of the present invention can be used not only in the cosmetic field such as prevention of skin aging, but also in the medical field, and is expected to be applied to cosmetics, quasi-drugs and medicines.
Claims (3)
これに用いるオウレンとして、オウレンを常圧にて９８〜１００℃の水によって１時間抽出し、固形分濃度が０．３重量％水溶液となるように調製したとき、その溶液のガードナー色数が７−から９−の色相を示すオウレンを用いることを特徴とする皮膚外用剤。 It is a skin external preparation containing an extract of an olivine,
As an olivine used for this, when an olivine is extracted with water at 98-100 ° C under normal pressure for 1 hour to prepare a solid content concentration of 0.3% by weight aqueous solution, the Gardner color number of the solution is 7 An external preparation for the skin characterized by using an orange exhibiting a hue of-to 9-.
これに用いるオウレンとして、オウレンを常圧にて９８〜１００℃の水によって１時間抽出し、固形分濃度が０．３重量％水溶液となるように調製したとき、その溶液のガードナー色数が７−から９−の色相を示すオウレンを用いることを特徴とする抗酸化剤。 An antioxidant containing an extract of olivine,
As an olivine used for this, when an olivine is extracted with water at 98-100 ° C under normal pressure for 1 hour to prepare a solid content concentration of 0.3% by weight aqueous solution, the Gardner color number of the solution is 7 An anti-oxidant characterized by using ouren having a hue of-to 9-.
これに用いるオウレンとして、オウレンを常圧にて９８〜１００℃の水によって１時間抽出し、固形分濃度が０．３重量％水溶液となるように調製したとき、その溶液のガードナー色数が７−から９−の色相を示すオウレンを用いることを特徴とする細胞増殖促進剤。 A cell growth promoter comprising an extract of urin,
As an olivine used for this, when an olivine is extracted with water at 98-100 ° C under normal pressure for 1 hour to prepare a solid content concentration of 0.3% by weight aqueous solution, the Gardner color number of the solution is 7 A cell growth promoting agent characterized by using an orange having a color of-to 9-.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017209186A JP7454203B2 (en) | 2017-10-30 | 2017-10-30 | Skin external preparations or internal preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017209186A JP7454203B2 (en) | 2017-10-30 | 2017-10-30 | Skin external preparations or internal preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019081719A true JP2019081719A (en) | 2019-05-30 |
| JP7454203B2 JP7454203B2 (en) | 2024-03-22 |
Family
ID=66671045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017209186A Active JP7454203B2 (en) | 2017-10-30 | 2017-10-30 | Skin external preparations or internal preparations |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7454203B2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH045237A (en) * | 1990-04-24 | 1992-01-09 | Nonogawa Shoji Kk | Superoxide eliminant |
| JP2011074022A (en) * | 2009-09-30 | 2011-04-14 | Maruzen Pharmaceut Co Ltd | PROMOTER FOR STEM CELL FACTOR (SCF) mRNA EXPRESSION |
| JP2013079242A (en) * | 2012-11-20 | 2013-05-02 | Ogawa & Co Ltd | Antioxidant plant extract, and preparation for external use, cosmetic, bathing agent, and detergent, each containing the extract |
-
2017
- 2017-10-30 JP JP2017209186A patent/JP7454203B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH045237A (en) * | 1990-04-24 | 1992-01-09 | Nonogawa Shoji Kk | Superoxide eliminant |
| JP2011074022A (en) * | 2009-09-30 | 2011-04-14 | Maruzen Pharmaceut Co Ltd | PROMOTER FOR STEM CELL FACTOR (SCF) mRNA EXPRESSION |
| JP2013079242A (en) * | 2012-11-20 | 2013-05-02 | Ogawa & Co Ltd | Antioxidant plant extract, and preparation for external use, cosmetic, bathing agent, and detergent, each containing the extract |
Non-Patent Citations (1)
| Title |
|---|
| FRAGRANCE JOURNAL, VOL.22,NO.2,1994.02, PP.38-42, JPN6021021055, ISSN: 0004519377 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7454203B2 (en) | 2024-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH07187989A (en) | Extracted solution of perilla frutescens and skin-beautifying cosmetic containing the same | |
| JP2006111545A (en) | Glutathione reductase activity-enhancing agent | |
| JP2002121112A (en) | Skin care preparation | |
| JP5184840B2 (en) | Topical skin preparation | |
| JP3742084B2 (en) | Mannentake extract by specific extraction method and production method thereof | |
| JP5138262B2 (en) | Topical skin preparation | |
| JP5154835B2 (en) | Whitening cosmetics | |
| JP4628604B2 (en) | Skin preparation | |
| JP2005023021A (en) | Elastase inhibitor | |
| JP2019081719A (en) | Skin external preparation or internal preparation | |
| JP3452671B2 (en) | External preparation for skin | |
| JP6281761B2 (en) | External preparation or internal preparation containing Hidakami Sebaya extract | |
| JP4748962B2 (en) | Moisturizer, cell activator, whitening agent, and antioxidant | |
| JP5468866B2 (en) | Topical skin preparation | |
| JP2001114664A (en) | Cosmetic | |
| JP5690149B2 (en) | External preparation or internal preparation | |
| KR100939658B1 (en) | Mixture extract of aged gallic, Melonis PedicellusCucumis melo var. makuwa MAKINO and Allii RadixAllium fistulosum L. | |
| JP4402274B2 (en) | Topical skin preparation | |
| KR20220088317A (en) | Anti-aging composition comprising fermented propolis | |
| JP4473439B2 (en) | Whitening agent | |
| JP6601959B2 (en) | Topical skin preparation | |
| JPH08175963A (en) | Skin preparation for external use | |
| JP4698810B2 (en) | Topical skin preparation | |
| JP2023180676A (en) | Carbonylation inhibitor | |
| JPH11124313A (en) | External preparation for skin whitening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200819 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210526 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210608 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210804 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211004 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220308 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231013 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240304 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7454203 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |